Neurotech Pharmaceuticals is a private clinical-stage biotech company dedicated to developing transformative therapies for chronic eye diseases. Their core platform technology, Encapsulated Cell Therapy (ECT), allows for the continuous production of therapeutic proteins specifically targeted at the eye. Their therapeutic area of focus is the retina, particularly Macular Telangiectasia (MacTel), a bilateral retinal disease that gradually erodes central vision.

Neurotech's ECT Platform releases Ciliary Neurotrophic Factor (CNTF), a protein that has been shown to protect against the progressive loss of photoreceptors, the main cause of MacTel. Currently, there are no known pharmacological treatment options available for MacTel. To stay at the forefront of science and technology, Neurotech has expanded its executive team and consistently publishes positive clinical trial results.

They are committed to improving the quality of life for individuals with chronic eye diseases and strive to develop innovative therapies that make a difference. With headquarters in Cumberland, RI, and a commercial office in Needham, MA, Neurotech Pharmaceuticals is leading the way in finding effective solutions for chronic eye diseases